Loading candles…
Ajanta Pharma Ltd. operates in the pharmaceutical industry, primarily engaged in developing, manufacturing, and marketing specialty pharmaceutical quality finished dosages. The company focuses on branded generic businesses across India, Asia, and Africa, and also maintains a presence in the United States generic market as well as institutional segments in Africa. Its product offerings include specialty pharmaceutical finished dosages and branded generics. Ajanta Pharma has a direct ground presence in over 30 countries and emphasizes high-margin branded generics along with a selective product strategy in regulated markets such as the US.
This page is a live market overview for AJANTA PHARMA LIMITED (AJANTPHARM) on the NSE. As a listed security, AJANTA PHARMA LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for AJANTPHARM before placing trades on tick2trade.
As of the latest feed, AJANTPHARM last traded at ₹3,489.2 on NSE, up ₹18.8 (0.54%) from the previous close of ₹3,470.4. Today's session range is ₹3,449 – ₹3,499.9, against a 52-week band of ₹2,329.9 – ₹3,598.8. Traded volume today stands at 34.85K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for AJANTPHARM in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether AJANTPHARM is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for AJANTA PHARMA LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in AJANTPHARM. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated AJANTPHARM option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 30 Jul 2026 |
| Dividend | To consider dividend | 30 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 5 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 30 Jan 2026 |
| Dividend | To consider dividend | 3 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 3 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 28 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 30 Apr 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.